Janus phenomenon: the interrelated tradeoffs inherent in therapies designed to enhance collateral formation and those designed to inhibit atherogenesis.
Epstein
Stephen E
SE
Cardiovascular Research Institute, Washington Hospital Center, 110 Irving St NW, 4B-1, Washington, DC 20010, USA. stephen.epstein@medstar.net
Stabile
Eugenio
E
Kinnaird
Timothy
T
Lee
Cheol Whan
CW
Clavijo
Leonardo
L
Burnett
Mary Susan
MS
D043925:Angiogenesis Inducing Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001161:Arteriosclerosis / Q000139:chemically induced* / Q000235:genetics / Q000517:prevention & control*; D018925:Chemokines / Q000502:physiology; D003097:Collateral Circulation / Q000187:drug effects*; D016207:Cytokines / Q000502:physiology; D018450:Disease Progression; D020022:Genetic Predisposition to Disease; D006801:Humans; D007249:Inflammation; D024821:Metabolic Syndrome / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D008954:Models, Biological; D009569:Nitric Oxide / Q000502:physiology; D016176:T-Lymphocyte Subsets / Q000276:immunology; D013997:Time Factors
D043925:Angiogenesis Inducing Agents; D020533:Angiogenesis Inhibitors; D018925:Chemokines; D016207:Cytokines; D009569:Nitric Oxide